7,8-dihydroxyflavone is a naturally-occurring phenolic flavone isolated from many natural sources. It has a diverse pharmacological profile, with anti-Parkinson's and anti-Alzheimer's effects in animal models. Although it affects numerous targets in the brain, it is primarily a TrkB agonist, and its main mechanism of action is by stimulating the release and production of a brain-derived neurotrophic factor (BDNF) called TrkB. Numerous clinical trials have assessed its activity as a nootropic, as a treatment mild cognitive impairment in adults, and in the treatment of Parkinson's disease.
7,8-dihydroxyflavone has somewhat low bioavailability and a short half-life. To bypass this, a novel drug (known as R7) has been developed as a prodrug for 7,8-dihydroxyflavone itself. It has vastly superior pharmacokinetics to 7,8-dihydroxyflavone, and has much higher bioavailability. It is quite likely that other O-acyl esters, such as acetyl, propanoyl, nicotinoyl and benzoyl esters, could acts as prodrugs for 7,8-dihydroxyflavone, and would offer improved pharmacokinetics compared to the parent drug itself. R7 also has been the subject of research, and currently is in the preclinical stage of development.
This compound is NOT intended for human consumption, and is for laboratory reagent or forensic/analytical purposes ONLY. The intent of its sale is agrochemical and other agricultural research.